Chemical, biochemical and genetic endeavours characterizing the interaction of sparsomycin with the ribosome.
Sparsomycin interaction with the ribosome and characteristics of the drug binding site in the particle were studied using chemical modification of the drug, affinity labeling methods and isolation of drug resistant mutants. The structure-function relationship studies, performed with a large number of drug derivatives, indicate that the drug interacts with the ribosome by its western and eastern moieties. The uracil ring, in the western end of the drug molecule, probably forms hydrogen bonds with the rRNA, while the apolar CH3-S-CH3 group in the eastern end interacts with a hydrophobic ribosomal domain that affinity labeling results seem to indicate is formed by protein. An increase in lipophilicity in this part of the antibiotic results in a dramatic increase in the inhibitory activity of the drug. The sparsomycin binding site is not accessible in free ribosomes, but the presence of an N-blocked amino acyl-tRNA at the P-site turns the particles capable of reversible interaction with the drug. After failure using Escherichia coli, a sparsomycin-resistant mutant was obtained by direct mutagenesis on Halobacterium halobium, a species with a unique copy of rRNA genes, stressing the role of rRNA on the drug interaction site.
Lazaro
E
E
Centro de Biologia Molecular, CSIC, Madrid, Spain.
Van den Broek
L A
LA
San Felix
A
A
Ottenheijm
H C
HC
Ballesta
J P
JP
D001665:Binding Sites; D004352:Drug Resistance, Microbial / Q000235:genetics; D019617:Halobacterium salinarum / Q000235:genetics / Q000378:metabolism; D009154:Mutation; D012329:RNA, Bacterial / Q000235:genetics / Q000378:metabolism; D012335:RNA, Ribosomal / Q000235:genetics / Q000378:metabolism; D012270:Ribosomes / Q000378:metabolism*; D013033:Sparsomycin / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism*; D013329:Structure-Activity Relationship
D012329:RNA, Bacterial; D012335:RNA, Ribosomal; D013033:Sparsomycin